Contineum Therapeutics files for IPO

Contineum Therapeutics has filed a $150 million IPO — adding to the growing list of biotechs with plans to go public this year. The clinical-stage San Diego biotech, which used to be called Pipeline Therapeutics, is developing small molecules for diseases like depression and idiopathic pulmonary fibrosis. The company was founded in 2009.